Trump to appeal tariff ruling, warns of economic consequences
Investing.com -- Private equity firm CapVest is set to acquire a majority stake in German pharmaceutical company Stada in a deal that values the company at approximately €10 billion ($11.7 billion), including debt.
CapVest announced Monday that it would purchase the controlling interest from current owners Bain Capital and Cinven.
While the financial terms of the transaction were not officially disclosed, the valuation figure is reported by Wall Street Journal.
The acquisition is expected to close in early 2026, according to CapVest’s statement.
The sale means Stada will not proceed with its planned initial public offering that had been targeted for this year, a Stada spokesman confirmed.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.